Novo Nordisk dramatically reduced its 2025 sales growth forecast to 8%-14% from a previous 13%-21%, citing ongoing challenges from lower sales of popular GLP-1 drugs due to knockoff competition. The Danish pharma also announced a CEO transition to insider Mike Doustdar alongside a leadership reorganization aimed at bolstering research and development efficiencies. The stock plunged over 20% on the news, reflecting investor concerns over the company’s near-term growth and competitive pressures in obesity and diabetes therapeutics.